中文摘要 |
Purpose: To monitor the effect, safety and tolerability of ezetimibe added to simvastatin in hypercholesterolemic patients using the hospital information system. Methods: A randomized control study was designed to evaluate the treatment goal attainment, safety and tolerability of ezetimibe added to simvastatin for the hypercholesterolemic patients in 4, 8 and 16 weeks. Results and Discussion: Treatment goals of lowering LDL-C, T-cholesterol , TG and elevating HDL-C were 71.2mg/dl (37.9%), 76.0mg/dl (31.1%), 34.0mg/dl (28.6%) and 3.0mg/dl (4.8%) in a simvastatin latter added ezetimibe group and 83.2mg/dl (49.6%), 86.0mg/dl (36.3%), 53.0mg/dl (34.9%) and 1.0mg/dl (3.0%) in an ezetimibe latter added simvastatin group, respectively. The ezetimibe simvastatin combination was no clinically significant elevations in hepatic transaminase or creatinine kinase and measures of hematology did not show any clinically significant differences. Conclusions: Ezetimibe was effective and well tolerated in this study, and ezetimibe was added to simvastatin that also found more significant lowering LDL-C, T-cholesterol and triglyceride and elevating HDL-C. |